More people are being identified with hemophilia B across the eastern Mediterranean region, suggesting…
Michela Luciano, PhD
Michela Luciano is a Science Writer at BioNews. Originally from the picturesque mountain town of L’Aquila, Italy, Michela holds a PhD in Molecular Biology from the University of Salzburg, where her research focused on the role of inflammation in acute myeloid leukemia. With a deep passion for scientific communication, Michela transitioned into her first role as a scientific writer in 2022. Outside of work, she enjoys street photography, mountain hikes, running, and spending as much time outdoors as possible.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Michela Luciano, PhD
Bleeding that persists or restarts after dental procedures may be an important warning sign of previously undiagnosed mild hemophilia,…
Artificial intelligence (AI) shows promise for helping doctors diagnose hemophilia, detect joint complications, and predict disease severity and other…
Preventive treatment with low-dose Hemlibra (emicizumab-KXWH) significantly reduced bleeding and improved quality of life in young children with hemophilia A,…
More than half of people with hemophilia receiving prophylactic (preventive) factor replacement therapies at two treatment centers in…
Heavy periods in teenage girls should prompt further evaluation for an underlying bleeding disorder, such as hemophilia, rather than simply being…
A gene therapy that delivers instructions to produce a longer-lasting version of the clotting protein missing or deficient in…
Caring for a child with hemophilia can bring emotional strain and disrupt family life even as advances in treatment make…
Women and girls with hemophilia continue to face delayed diagnoses, unequal access to treatment, and underrepresentation in clinical trials,…
Long-term treatment with Hemlibra (emicizumab) provided sustained protection against bleeding for up to five years in people with…